FV-100: Completed Phase II enrollment

Inhibitex completed enrollment of 350 patients in a double-blind Phase II trial comparing 200 and 400 mg doses of once-daily FV-100 vs. 1,000 mg thrice-daily Valtrex valacyclovir. In July, an indepen...